BioCryst Pharmaceuticals
BCRX
BCRX
195 hedge funds and large institutions have $1.65B invested in BioCryst Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
195
Holders Change
+4
Holders Change %
+2.09%
% of All Funds
3.4%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
41
Increased
61
Reduced
61
Closed
36
Calls
$81.8M
Puts
$68.5M
Net Calls
+$13.3M
Net Calls Change
-$610K
Top Buyers
| 1 |
Fisher Asset Management
Camas,
Washington
|
$31.8M |
| 2 |
Two Sigma Investments
New York
|
$29.3M |
| 3 |
Renaissance Technologies
New York
|
$16.3M |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
$24.7M |
| 5 |
D.E. Shaw & Co
New York
|
$13.8M |
